Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

ADT

DRUG

Brexpiprazole

Trial Locations (24)

10305

Behavioral Medical Research of Staten Island, Staten Island

18104

Lehigh Center for Clinical Research, Allentown

21208

Pharmasite Research, Baltimore

27609

Richard H. Weisler, MD, PA, Raleigh

30080

Carman Research, Smyrna

32806

Clinical Neuroscience Solutions Pharmacology, Orlando

38119

Research Strategies of Memphis, LLC, Memphis

46260

Goldpoint Clinical Research, Indianapolis

47905

Alpine Clinic, Lafayette

48307

Rochester Center for Behavioral Medicine, Rochester Hills

63118

St. Louis Clinical Trials, St Louis

73116

Cutting Edge Research Group, Oklahoma City

75231

Future Search Trials of Dallas, LP, Dallas

92591

Viking Clinical Research, Ltd., Temecula

92845

Collaborative NeuroScience Network, Inc., Garden Grove

97210

Oregon Center for Clinical Investigations, Inc., Portland

97301

Oregon Center for Clinical Investigations, Inc., Salem

99204

Frontier Institute, Spokane

02131

Boston Clinical Trials, Boston

02190

Coastal Research Associates, Inc., Weymouth

08002

Center for Emotional Fitness, Cherry Hill

45417-3445

Midwest Clinical Research Center MCRC, Dayton

02865

Lincoln Research, LLC, Lincoln

05091

NeuropsychiatricAssociates, Woodstock

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY